To enable our clients to bring healthcare products to market — safely, compliantly, and across borders.
Most companies publish values that could belong to anyone. Integrity. Excellence. Innovation. They are pleasant, and they commit you to nothing.
We would rather publish principles we can actually be held to — the ones a client could point at and say you did not do that. Each of the five below carries a consequence. Several of them cost us work.
“In this industry, an inconvenient answer given early is worth more than a comfortable one given late.”
Dr. Arshia Parveen — DirectorIt is easy to tell a client their product will sail through a market. It is harder to say that their formulation sits above the permitted dose limit, that their manufacturing site will not satisfy the regulator, or that the market they have set their heart on will not accept the product for another year.
We say it anyway, at the start, when it is still cheap to act on. A project stopped in month one costs a conversation. The same project stopped after a rejection costs a year and a dossier.
This principle sometimes ends the engagement. We accept that.
No consultant controls a regulator’s review queue. Published approval timelines describe an authority’s assessment clock — not elapsed calendar time, and not the weeks your team spends answering deficiency questions.
So we do not quote approval dates, and we are wary of anyone who does. What we will do is scope your product honestly and tell you what genuinely drives the schedule: dossier quality, GMP evidence, and how fast you respond.
You will not find a single approval timeline published on this website. Check.
A supplement made on a food-grade line may pass in one market and be blocked outright in another. Several Gulf regulators expect pharmaceutical-grade GMP for capsule and tablet forms, whatever the product is called.
We build to the strictest requirement in your target set, not the easiest one that will technically pass. It costs more at the start. It is considerably cheaper than discovering the gap after a rejection.
Manufacturing decisions are market-access decisions.
A health claim that cannot be substantiated is not a marketing problem to be solved later — it is a formulation and evidence problem that starts on day one. A single claim can move a product from a supplement pathway into a drug pathway and change everything that is required of it.
We review claims at development stage, not at artwork stage. Where a requirement is genuinely uncertain, we say so and confirm it with the authority rather than guess.
Every deliverable is a draft until a qualified professional approves it.
The most expensive failures in product development happen in the gaps between vendors — where the formulator assumed the regulatory consultant had checked something, and neither did.
Formulation, stability, sourcing, quality and registration sit under one roof at Raised Pharma. When something goes wrong, there is no one for us to point at. We consider that the correct arrangement.
No hand-offs. No gaps. One point of responsibility.
Values written on a website are worth nothing on their own. These are worth something only if you test them.
So test them. Ask us for an approval timeline and see whether we invent one. Ask whether your existing manufacturing site will satisfy the market you want, and see whether we tell you what you want to hear. Ask about a requirement we are not certain of, and see whether we say we will confirm that or simply assert an answer.
How a partner behaves in the first conversation is a reliable guide to how they will behave in month eleven.
Email: info@raisedpharma.com Phone: +1 (716)-777-4800
Start a conversation Meet our leadership About Raised Pharma